Piramal looks for 20% RoI from investment in Vodafone India but not mHealth tie-up yet
This article was originally published in Scrip
Executive Summary
Piramal Healthcare has acquired an additional 5.5% in Vodafone India from ETHL Communications Holdings (Essar) for about $600 million, as part of ongoing efforts to park funds in high-growth areas that offer better returns for the short and medium term. According to the pharma company, the move is a strictly financial venture from which it is hoping for up to a 20% return on investment, rather than a strategic move towards the application of mobile communications and network technologies for healthcare, or mHealth.
You may also be interested in...
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet
Astellas CStO Pearson: We’re Not Short Of Opportunities To Compensate For LOEs
Astellas’ chief strategy officer, Adam Pearson, talks to Scrip about the company’s launch execution thrust for key therapies ahead of the loss of exclusivity for Xtandi and also deal-making appetite and choices, including the Iveric Bio buyout and walking away from the collaboration with Cartesian Therapeutics.